Facilities & Capacity

Lithuanian CDMO Northway invests $40m in MA plant

Northway will open a facility in Waltham offering microbial and mammalian cell line development and upstream and downstream process advancement. The contract development manufacturing organization (CDMO) headquartered in Vilnius, Lithuania opened its doors to international ministers for a tour of its 30,000 square foot sister facility in Waltham, which is expected to be fully operational by the end of 2022. “We selected Waltham because of its close proximity to the Boston biotech cluster, one of the premier global life sciences hubs…

Korean CDMO enters US with BMS plant buy

Lotte is set to buy Bristol-Myers Squibb’s (BMS) facility in East Syracuse, which it says will serve its CDMO business in the US. The deal, which is subject to regulatory approvals and other closing conditions, sees Korean-based firm Lotte Corporation acquire BMS’ New York site’s operations and assets. This includes the equipment, property, plant, workforce, and technical capabilities. “This transaction is consistent with our longstanding goal of creating a manufacturing network to best support the ongoing needs of the business…

PCI forks out $100m to expand New England plant

The Philadelphia-based CDMO will expand its capacity in sterile lyophilization technology and aseptic liquid fill/finish to stay ahead of demand. PCI Pharma Services says the investment of $100 million at its Bedford, New Hampshire campus will include a 50,000 square-foot facility, which will enable the contract development manufacturing organization (CDMO) to expand its service offerings in biologics packaging and manufacturing. “We are excited to introduce clients to our newest facility, which is part of our broader strategy to provide integrated…

ALSA latest VC firm to contract Lonza to service its portfolio

Lonza says small to mid-sized companies represent the bulk of its customers as it adds ALSA Ventures’ biopharma portfolio to its client list. The deal will see Swiss contract development and manufacturing organization (CDMO) help develop and manufacture European biotech investment firm ALSA has contracted Lonza to help develop and manufacture molecules within its biologics and small molecule company portfolio. The deal, financials of which have not been divulged, will see ALSA’s portfolio companies – which include Promatix, Montis Biosciences,…

Bora Pharmaceuticals bolsters CDMO biz with Eden buy

As part of its five-year plan, Bora Pharmaceuticals will initially invest $50 million to acquire the CDMO assets of Eden Biologics in Taiwan. Taiwan-based contract development manufacturing organization (CDMO) Bora Pharmaceuticals has said it will initially invest $50 million and up to $100 million to acquire Eden’s CDMO assets. Through the acquisition, Bora will gain assets located in Hsinchu Biomedical Science Park, Taiwan. According to the CDMO, this will build and expand its presence in the biological macromolecule and cell…

Emergent ditched 400m vaccines amid quality and staff issues, report finds

Emergent BioSolutions hid evidence of contamination and destroyed nearly 400 million doses of J&J and AstraZeneca vaccines, a US Government staff report has found. Emergent was one of the benefactors from the US Government’s efforts in countering COVID-19, winning a Trump Administration contract worth $628 million to make the Johnson & Johnson (J&J) and AstraZeneca vaccines. However, the contract development and manufacturing organization (CDMO) was hit with an FDA Form 483 and a directive to stop production at its Bayview,…

Inventprise opens Washington pneumococcal vaccine plant

Inventprise will carry out fill-finish for its pneumococcal disease vaccine, IVT-PCV-25 at its newly opened facility in Woodinville. Inventprise, a firm that specializes in affordable vaccines and is supported by the Bill & Melinda Gates Foundation (BMGF), has announced the inauguration of its manufacturing facility intended for high-capacity supply of a 25-valent Pneumococcal Conjugate Vaccine (IVT-PCV-25) for distribution to low-and-middle-income countries. IVT-PCV-25 is being developed by Inventprise in partnership with non-profit global health organization PATH. According to the firm, the…

EureKING aims to create €1bn+ CDMO via EU SPAC

A group of biopharma pioneers have teamed up to raise $158 million to create a European bio-CDMO.   EureKING, a “blank-check” company — also known as a special-purpose acquisition company, or SPAC — claims to be the first European SPAC in healthcare devoted to biomanufacturing. The company aims to form a contract development manufacturing organization (CDMO) to be listed on Euronext Paris. To do so, eureKING is looking to raise €150 million ($158 million), which could be increased to €165…

Robo-bloc: Multiply labs welcomes Thermo Fisher and Charles River

Thermo Fisher Scientific and Charles River will join Multiply Labs, which aims to develop and validate a robotic manufacturing system that can produce gene modified cell therapies. Multiply Labs founded the robotic cell therapy manufacturing Consortium in 2021 and had initial participation from Cytiva and the University of California, San Francisco (UCSF). Now, Thermo Fisher and Charles River Laboratories have joined as Consortium members. According to Multiply Labs, traditional manufacturing processes can require hours of manual manipulation of cells and…

Regenxbio: ‘CDMO issue validates inhouse gene therapy investment’

Regenxbio will begin inhouse production of material for its Duchenne Muscular Dystrophy (DMD) gene therapy after a quality issue at a third-party manufacturer delayed clinical trial dosing. The initiation of dosing adeno-associated viral (AAV) based gene therapy candidate RGX-202 for a Phase I/II clinical trial has been delayed by between six and 12 months, Regenxbio announced last week during its first quarter 2022 financial results. According to CEO Ken Mills, the delay is due to an issue at an undisclosed contract…